Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ambrisentan in Early Idiopathic Pulmonary Fibrosis
2008-004405-34Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jan 2009; status: terminated.
02
Drugs
ambrisentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2008-004405-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004405-34.